Form 4: Agios Director Scadden Exercises, Sells Shares

Agios Pharmaceuticals Director David Scadden exercised stock options and subsequently sold an equal number of common shares on September 30, 2025, under a pre-arranged trading plan.

Summary

• David Scadden, a Director of Agios Pharmaceuticals, Inc. (AGIO), engaged in a transaction involving the company's common stock.
• On September 30, 2025, Scadden acquired 200 shares of common stock by exercising stock options at a price of $18.09 per share.
• Immediately following the acquisition, Scadden disposed of 200 shares of common stock at a price of $40.00 per share.
• Both transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was pre-adopted by the reporting person.
• Following these transactions, Scadden's direct beneficial ownership of common stock is 17,603 shares.
• The stock options exercised were granted on June 21, 2022, and vested 100% one year from the grant date.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned insider activity involving a very small number of shares, indicating a neutral impact on overall company sentiment.

Positives

• The director's exercise of options indicates a realization of value from previously granted equity compensation.
• The sale price of $40.00 per share is significantly higher than the exercise price of $18.09, demonstrating a profitable transaction for the director.
• The transaction was executed under a Rule 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations by pre-scheduling trades.

Negatives

• The sale of shares by a director, even if pre-planned, could be perceived by some investors as a lack of conviction, although the number of shares is very small.

Future Outlook

This Form 4 filing is a disclosure of past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure for a publicly traded company and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual director's equity compensation management.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of a very small number of shares by a director is unlikely to have a material impact on the company's stock price or investor sentiment.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, Form 4, Insider Transaction, Stock Options, Share Sale, Director, 10b5-1 Plan